In-Licensing: Strategies for Success
Pharmaceutical companies rely on in-licensing to enhance their product pipeline and ultimate product portfolio at a reasonable price. This three-page research summary describes and provides excerpts from two key pieces of research -- "Winning Strategies in Developing Criteria for Compound Evaluations" and "Top Success Factors for Effective In-Licensing Organizations". This research, contained in the Pharma & Life Sciences Database along with many other related documents, will allow pharmaceutical business development and deal-making staff and biotech counterparts to understand which strategies best suit their own needs and the what key components they need to effectively implement those strategies.
The research summary will also reference other related research on in-licensing and outline a special offer -- that any Database document purchases can be credited toward a full access membership to the Pharma & Life Sciences Database within 30 days of the date of the document(s) purchase.
Industries Profiled:
Pharmaceutical; Diagnostic; Biotech; Health Care
Companies Profiled:
Aventis; Roche; Bristol-Myers Squibb; GlaxoSmithKline ; Novartis; Wyeth; AstraZeneca Pharmaceuticals; Genentech; Johnson & Johnson
Special Offer: If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call J.B. Barrow at 919-767-9229 if you have any questions.
|